Trial Profile
A Phase 1 Study of The Safety and Tolerability of COM902 in Subjects With Advanced Malignancies
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs COM 701 (Primary) ; COM 902 (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Carcinoma; Colon cancer; Colorectal cancer; Fallopian tube cancer; Head and neck cancer; Multiple myeloma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Rectal cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Pharmacokinetics; Proof of concept
- Sponsors Compugen
- 05 Mar 2024 According to a Compugen media release, data from platinum resistant ovarian cancer patients expected in the fourth quarter of 2024
- 10 Feb 2024 Planned End Date changed from 30 Jun 2024 to 30 Mar 2025.
- 10 Feb 2024 Planned primary completion date changed from 30 Dec 2023 to 30 Dec 2024.